Activity and tolerability of nilotinib-Reference-Cited by-同舟云学术

Activity and tolerability of nilotinib

Published:2010-08-19 Issue:19 Volume:116 Page:4564-4572
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Koren-Michowitz Maya,le Coutre Philipp,Duyster Justus,Scheid Christof,Panayiotidis Panayiotis,Prejzner Witold,Rowe Jacob M.,Schwarz Michaela,Goldschmidt Neta,Nagler Arnon

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference25 articles.

1. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia;Hochhaus;Leukemia.,2009

2. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy;Hochhaus;Leukemia.,2002

3. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia;Golemovic;Clin Cancer Res.,2005

4. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107);von Bubnoff;Blood.,2006

5. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance;Kantarjian;Blood.,2007

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is dose modification or discontinuation of nilotinib necessary in nilotinib-induced hyperbilirubinemia?;World Journal of Meta-Analysis;2021-12-28

2. Nilotinib-induced liver injury;Medicine;2020-09-04

3. Nilotinib treatment induced large granular lymphocyte expansion and maintenance of longitudinal remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia;International Journal of Hematology;2020-01-01

4. Chemotherapy and Beyond;Infectious Disease Clinics of North America;2019-06

5. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors);Clinical Microbiology and Infection;2018-06